Lilly's Taltz(R) (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

Taltz is now approved to treat patients across the full axSpA spectrum, including ankylosing spondylitis (AS), also known as radiographic axSpA, and nr-axSpA INDIANAPOLIS, June 1, 2020 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company ... Biopharmaceuticals, FDA Eli Lilly, Taltz, ixekizumab, spondyloarthritis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news